The distribution of the cost of multiple sclerosis in the UK: How do costs vary by illness severity?

Value in Health

Volumn 10, Issue 5, 2007, Pages 386-389

  Tyas, David ^a   Kerrigan, John ^a   Russell, Nicola ^b   Nixon, Richard ^c  

^a Heron Evidence Development Ltd   (United Kingdom)

^b MS Trust   (United Kingdom)

^c MRC BIOSTATISTICS UNIT   (United Kingdom)

Author keywords

Cost; Multiple sclerosis; Study; UK

Indexed keywords

ARTICLE; COST OF ILLNESS; COVARIANCE; DEMOGRAPHY; DISEASE SEVERITY; HEALTH CARE PLANNING; HUMAN; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; RELAPSE; STATISTICAL MODEL; UNITED KINGDOM;

EID: 34748843196     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2007.00192.x     Document Type: Article

References (7)

1. Quarles R, Morell P, McFarland H. Diseases involving myelin. In : Siegel G, Agranoff B, Albers R, et al., eds., Basic Neurochemistry, Molecular, Cellular, and Medical Aspects (6th ed). Philadelphia, PA : Lippincott, Williams & Wilkins, 1999.
2. Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life in multiple sclerosis in Europe. J Neurol Neurosurg Psychiatry 2006 77 : 918 26.
3. Orme M, Kerrigan J, Tyas D, et al. The effect of disease, disability and relapses on the utility of people with multiple sclerosis in the UK. Value Health 2007 10 : 54 60.
4. Henriksson F, Fredrikson S, Masterman T, Jonsson B. Costs, quality of life and disease severity in multiple sclerosis: a cross-sectional study in Sweden. Eur J Neurol 2001 8 : 27 35.
5. Greene WH. Econometric Analysis (5th ed). Upper Saddle River, NJ, Prentice Hall, 2003.
6. The R Project for Statistical Computing. The GNU Operating System Available from: http://www.r-project.org/ [Accessed August 18, 2006].
7. Association of British Neurologists. Guidelines for the Use of Beta Interferons and Glatiramer Acetate in Multiple Sclerosis, 2001. Available from: http://www.theabn.org/downloads/msdoc.pdf [Accessed March 22, 2007].